Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development
of RNAi-based therapeutics, today announced the presentation of
preclinical data demonstrating the promise of DCR-PH1, the Company’s
therapeutic candidate for the treatment of primary hyperoxaluria type 1
(PH1), a rare inherited liver disorder that often results in progressive
and severe kidney damage.
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage
biopharmaceutical company developing nucleic acid therapeutics for
patients with cancer and rare diseases, today announced the publication
of promising preclinical data demonstrating the application of the
Company’s novel Gene Silencing Oligonucleotides (GSOs) to inhibit
microRNAs implicated in neovascularization, a process that involves the
proliferation of blood vessels in tissue and is crucial for recovery
following cardiovascular events.
By James Marson in Moscow and Laurence Norman in Brussels
Ukrainian President Petro Poroshenko said Wednesday that Russia had withdrawn most of its troops from eastern Ukraine, raising further hopes that a peace deal struck last week would stick.
HILDEN , Germany , and MARSEILLE, France , July 24, 2014 /PRNewswire/ --
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for blood cancers Mutations of SF3B1 gene, to be targeted by new test, indicate favorable prognosis for patients with bone marrow disorders known as myelodysplastic syndromes QIAGEN sees potential for developing companion diagnostics to guide treatment with new anti-cancer compounds under development that target the SF3B1 gene QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has acquired an exclusive global license to the biomarker SF3B1 from the University of Tokyo .
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.